The effect of sotagliflozin in the SCORED (Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) trial demonstrated that dual SGLT1 and 2 inhibitor (SGLT1/2i) reduced the risk of primary outcomes of death from cardiovascular causes and hospitalizations and urgent visits for HF across those with diabetes and CKD, regardless of albuminuria.22 Here, SLC5A1 is linked to hydrops fetalis.